Jump to ContentJump to Main Navigation

Online

249,00 € / $374.00*

* Prices subject to change. Shipping costs will be added if applicable.
Publication Date:
May 2012
ISSN:
1437-4315
DOI:
10.1515/bc-2011-231

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 249.00
RRP for USA, Canada, Mexico
US$ 374.00 *
Print
Individual Subscription Online only
Euro [D] 1566.00
RRP for USA, Canada, Mexico
US$ 2349.00 *
Print + Online
Individual Subscription Online only
Euro [D] 1880.00
RRP for USA, Canada, Mexico
US$ 2819.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Ludwig, Stephan / Sies, Helmut / Stoffel, Markus / Turk, Boris / Wittinghofer, Alfred / Baumeister, Wolfgang / Bergeron, John / Bogyo, Matthew / Bürkle, Alexander / Cadenas, Enrique / Chiti, Fabrizio / Dikic, Ivan / Dobson, Christopher / Driessen, Arnold / Fritz, Hans / Gevaert, Kris / Hammann, Christian / Hartl, F. Ulrich / Häussinger, Dieter / Hiscott, John / Igarashi, Yasuyuki / Klotz, Lars-Oliver / Krüger, Achim / Magdolen, Viktor / Müschen, Markus / Narumiya, Shuh / Naumann, Michael / Pejler, Gunnar / Pfanner, Nikolaus / Pike, Robert / Potempa, Jan / Saftig, Paul / Sandhoff, Konrad / Schaffner, Walter / Sinning, Irmgard / Sommerhoff, Christian P.

12 Issues per year

IMPACT FACTOR 2011: 2.965
Rank 130 out of 289 in category Biochemistry and Molecular Biology in the 2011 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors

Hyunjae Chung1 / Magda Hamza2 / Katerina Oikonomopoulou1, 3, 4 / Valérie Gratio2 / Mahmoud Saifeddine1 / G. Duke Virca5 / Eleftherios P. Diamandis3 / Morley D. Hollenberg1 / 2

1Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, T2N 1N4, Canada

2Institut National de la Santé et de la Recherche Médicale (INSERM) U773, Centre de Recherche Biomédicale Bichat-Beaujon, 75018 Paris, France

3Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, M5G 1X5, ON, Canada

4Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA

5Inflammation Research, Amgen Inc., Seattle, WA 98119, USA

Corresponding author

Citation Information: . Volume 393, Issue 5, Pages 413–420, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: 10.1515/bc-2011-231, May 2012

Publication History:
Received:
2011-10-18
Accepted:
2011-12-05

Abstract

We hypothesized that kallikrein-related peptidase 14 (KLK14) is produced by colonic tumors and can promote tumorigenesis by activating proteinase-activated receptors (PARs). We found that KLK14 is expressed in human colon adenocarcinoma cells but not in adjacent cancer-free tissue; KLK14 mRNA, present in colon cancer, leads to KLK14 protein expression and secretion; and KLK14 signals viaPAR-2 in HT-29 cells to cause (1) receptor activation/internalization, (2) increases in intracellular calcium, (3) stimulation of ERK1/2/MAP kinase phosphorylation, and (4) cell proliferation. We suggest that KLK14, acting via PAR-2, represents an autocrine/paracrine regulator of colon tumorigenesis.

Keywords: cancer; colon; kallikrein; PARs; proliferation; signaling

Comments (0)

Please log in or register to comment.